Indrayani Biotech Limited announced its unaudited financial results for the quarter ended December 31, 2025, along with significant leadership changes and strategic financial decisions. The Board of Directors, meeting on February 26, 2026, approved the quarterly results and made several important corporate announcements.

Financial Performance Overview

The company's standalone financial performance for Q3FY26 showed mixed results compared to the previous year. Revenue from operations declined to ₹520.10 lakhs from ₹818.82 lakhs in the corresponding quarter of the previous year. Despite the revenue decline, the company maintained profitability with a net profit of ₹8.02 lakhs compared to ₹10.61 lakhs in Q3FY25.

Consolidated Results Show Stronger Performance

On a consolidated basis, Indrayani Biotech demonstrated significantly stronger performance. Consolidated revenue from operations reached ₹3,501.48 lakhs for Q3FY26, substantially higher than ₹1,731.82 lakhs in the corresponding quarter of the previous year. The consolidated net profit stood at ₹11.55 lakhs compared to ₹35.15 lakhs in Q3FY25.

Leadership Transition in Finance Function

The Board approved significant changes in the company's finance leadership. Mr. Dhinakaran Rajagopal resigned from his position as Chief Financial Officer effective February 26, 2026, citing personal reasons. The company simultaneously appointed Mr. Kunisetty Venkateswara Rao as the new Chief Financial Officer, effective February 27, 2026.

Mr. Kunisetty Venkateswara Rao brings extensive experience to the role:

• Qualified Chartered Accountant and Bachelor in Commerce
• Fellow Member of the Institute of Chartered Accountants of India (ICAI)
• Over 30 years of experience in financial management, corporate finance, and strategic planning
• Expertise in taxation, audit, compliance, and regulatory matters

Strategic Financial Initiatives

The Board approved several strategic financial decisions to support the company's growth objectives. The company secured approval for credit facilities worth ₹5 crores from Indus Finance Limited, which will provide additional financial flexibility for operations and expansion.

Regarding the Rights Issue, the company received in-principle approval from BSE Limited on September 19, 2025, for its proposed partly paid-up Rights Issue. The Board resolved to expedite this process and complete the Rights Issue within prescribed timelines in compliance with SEBI (ICDR) Regulations, 2018.

Compliance and Regulatory Matters

The Board addressed previous compliance issues with BSE Limited regarding delays in regulatory filings. The company faced fines for late submission of financial results for September 2025 under Regulation 33 (₹1,47,500) and delays in board meeting intimations under Regulation 29 (₹11,800). Both fines have been paid and the matters now stand resolved.

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the standalone performance showed revenue from operations of ₹1,781.80 lakhs with net profit of ₹67.63 lakhs. On a consolidated basis, the company achieved revenue of ₹10,006.70 lakhs with net profit of ₹118.41 lakhs, demonstrating the strength of the group's diversified operations across its subsidiary companies.

Indrayani Biotech Limited has received a SARFAESI (Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest) notice from Hinduja Leyland Finance Limited regarding the classification of its credit facilities as Non-Performing Assets (NPA). The company disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

SARFAESI Notice Details

The SARFAESI Demand Notice was published by Hinduja Leyland Finance Limited in 'The New Indian Express' on January 30, 2026. The notice indicates that term loans provided by the Non-Banking Financial Company (NBFC) have been classified as NPA due to non-payment of principal and interest installments.

Default Amount and Loan Structure

According to the regulatory filing, the current default amount as a borrower stands at Rs. 47,56,159.60, while as a co-borrower along with seven other co-borrowers, the default amount is Rs. 1,40,69,822.96. The loan facilities have specific terms and conditions that highlight the company's financial obligations.

Financial Indebtedness Overview

The disclosure reveals the company's broader financial obligations beyond the specific SARFAESI notice. The total amount of outstanding borrowings from banks and financial institutions stands at Rs. 41,00,01,653. Additionally, the company's total financial indebtedness, including both short-term and long-term debt, amounts to Rs. 54,48,47,022.

Company's Response and Next Steps

Indrayani Biotech Limited has stated that it is currently evaluating the contents of the SARFAESI notice. The company has indicated its intention to take all necessary actions to regularize the accounts and protect the interests of all stakeholders. This response suggests the company is actively working to address the NPA classification and resolve the outstanding obligations with Hinduja Leyland Finance Limited.

The disclosure was made on January 31, 2026, as part of the company's compliance obligations under SEBI regulations, ensuring transparency for investors and stakeholders regarding material developments affecting the company's financial position.